| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma |
NCT05635487: A Study of SHR-A1811 Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients |
|
|
| Recruiting | 2 | 61 | RoW | SHR-A1811, Pyrotinib | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | HER2-positive Breast Cancer | 02/24 | 02/29 | | |
NCT06340230: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer |
|
|
| Not yet recruiting | 2 | 93 | RoW | SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | ER Positive/HER2 Low Breast Cancer | 02/26 | 02/31 | | |
NCT06413745: Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 65 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | HER2 Expression / Amplification in Patients With Biliary Tract Cancer | 09/25 | 09/25 | | |
NCT05349409: A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers |
|
|
| Enrolling by invitation | 2 | 212 | RoW | SHR-A1811, Fluzoparib Capsule, SHR-3162 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 11/24 | 05/25 | | |
NCT05353361: A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer |
|
|
| Recruiting | 2 | 402 | RoW | SHR-A1811：Pyrotinib, SHR-A1811；Pertuzumab, SHR-A1811；Adebrelimab, SHR-A1811；Albumin paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05896020: A Study of SHR-A1811 in Subjects With Gynaecologic Oncology |
|
|
| Recruiting | 2 | 225 | RoW | SHR- A1811 | Jiangsu HengRui Medicine Co., Ltd. | Gynaecological Malignancies | 06/26 | 06/26 | | |
NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer |
|
|
| Recruiting | 2 | 156 | RoW | SHR-A1811；SHR-1701；capecitabine；oxaliplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 07/26 | 07/26 | | |
NCT04818333: A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 157 | RoW | SHR-A1811 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/25 | 06/25 | | |
NCT05482568: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 324 | RoW | SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Non-small Cell Lung Cancer | 11/23 | 12/24 | | |
NCT06222879: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 1/2 | 350 | NA | HRS-8080; SHR-A1811, HRS-8080; SHR-A2009, SHR-A2009; SHR-1316 | Shandong Suncadia Medicine Co., Ltd. | Breast Cancer | 10/26 | 10/26 | | |
NCT05792410: A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. |
|
|
| Not yet recruiting | 1/2 | 300 | NA | SHR-A1811 & Dalpiciclib Isethionate Tablets, SHR-A1811 & Fulvestrant, SHR-A1811 & Bevacizumab injection | Jiangsu HengRui Medicine Co., Ltd. | HER2 Low Advanced or Metastatic Breast Cancer | 02/24 | 02/25 | | |
NCT05845138: A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. |
|
|
| Recruiting | 1/2 | 116 | RoW | SHR-A1811 for injection ; capecitabine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Breast Cancer | 12/24 | 12/25 | | |
NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
